RT Journal Article
SR Electronic
T1 Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21258686
DO 10.1101/2021.06.21.21258686
A1 Ulrike Baum
A1 Eero Poukka
A1 Arto A. Palmu
A1 Heini Salo
A1 Toni O. Lehtonen
A1 Tuija Leino
YR 2021
UL http://medrxiv.org/content/early/2021/06/28/2021.06.21.21258686.abstract
AB Background In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after the vaccination campaign started on December 27, 2020. Vaccination of the elderly and chronically ill was prioritized and the interval between doses set to 12 weeks. The objective of this interim analysis was to evaluate first and second dose vaccine effectiveness (VE) in a real-world setting.Methods During the first 5 months of the campaign, a register-based cohort study was conducted in the Finnish elderly aged 70+ years and those aged 16–69 years with medical conditions predisposing to severe Covid-19 (chronically ill). Using Cox regression, VE against SARS-CoV-2 infection and Covid-19 hospitalization was estimated comparing the hazard in the vaccinated with that in the unvaccinated.Results The cohorts included 901092 elderly (89% vaccinated) and 774526 chronically ill (69% vaccinated) individuals. Three weeks after the first dose, mRNA VE against infection was 45% (95% confidence interval, 36–53%) and 40% (26–51%) in elderly and chronically ill; mRNA VE against hospitalization was 63% (49–74%) and 82% (56–93%). In chronically ill, AdV VE was 42% (32–50) and 62% (42– 75%) against infection and hospitalization, respectively. One week after the second dose, mRNA VE against infection was 75% (65–82%) and 77% (65–85%) in elderly and chronically ill; mRNA VE against hospitalization was 93% (70–98%) and 90% (29–99%).Conclusions Covid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalization. A single dose provides moderate protection in elderly and chronically ill, although 2 doses are clearly superior.summary This register-based cohort study demonstrates that Covid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill. Vaccine effectiveness against hospitalization was moderate after 1 dose and increased to ≥90% after 2 doses.Competing Interest StatementAAP is an investigator in studies for which the Finnish Institute for Health and Welfare has received research funding from Sanofi Pasteur, GlaxoSmithKline and Pfizer. All other authors declare no conflict of interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Under Finnish law, THL is the national expert institution in Finlnad to carry out surveillance on the impact of vaccinations (Communicable Diseases Act, https://www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf) and specific ethical approval was not needed. The supplements material includes THL Director of the Department for Health Security signatured statement considering the ethical review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBy Finnish law, the authors are not permitted to share individual-level register data. The computing code is available upon request.